MORRISVILLE, N.C.--(BUSINESS WIRE)--
Oxygen Biotherapeutics, Inc. (OXBT) today announced that the Company plans to report second quarter fiscal year 2013 financial results on Form 10-Q on Friday, December 14, 2012. Oxygen’s President and Chief Financial Officer Michael Jebsen will host a conference call and live webcast to discuss the results on Monday, December 17, 2012, at 11 a.m. EST.
To access the live teleconference, dial (800) 299-9630 (U.S. and Canada) or (617) 786-2904 (international.) The participant passcode is 40837151. A live webcast will be available on our web site http://www.oxybiomed.com/investors.htm.
A replay of the webcast will be available on the Oxygen website, or by phone for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international). The passcode for the replay is 90794929.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market.
Ellen Corliss
Senior Vice President
Corporate Communications & Investor Relations
919-855-2112
